Induction of somatopause in adult mice compromises bone morphology and exacerbates bone loss during aging. Somatopause refers to the gradual declines in growth hormone (GH) and insulin-like growth factor-1 throughout aging. To define how induced somatopause affects skeletal integrity, we used an inducible GH receptor knockout (iGHRKO) mouse model. Somatopause, induced globally at 6 months of age , resulted in significantly more slender bones in both male and female iGHRKO mice. In males, induced somatopause was associated with progressive expansion of the marrow cavity leading to significant thinning of the cortices, which compromised bone strength. We report progressive declines in osteocyte lacunar number, and increases in lacunar volume, in iGHRKO males, and reductions in lacunar number
Sexual dimorphic impact of adult-onset somatopause on life span and age-induced osteoarthritis. Osteoarthritis (OA), the most prevalent joint disease, is a major cause of disability worldwide. Growth hormone (GH) has been suggested to play significant roles in maintaining articular chondrocyte function and ultimately articular cartilage (AC) homeostasis. In humans, the age-associated decline
Somatopause, weaknesses of the therapeutic approaches and the cautious optimism based on experimental ageing studies with soy isoflavones The pathological phenomenon of somatopause, noticeable in hypogonadal ageing subjects, is based on the growth hormone (GH) production and secretion decrease along with the fall in GH binding protein and insulin-like growth factor 1 (IGF-1) levels, causing already demonstrated the health benefits in treated elderly, at least experimentally reveal their potential for the somatopausal symptoms remediation. Namely, genistein enhanced GHRH-stimulated cAMP accumulation and GH release in rat anterior pituitary cells; refreshed and stimulated the somatotropic system (hypothalamic nuclei and pituitary GH cells) function in a rat model of the mild andropause
referred to as somatopause contributes to this loss. Interventions targeting this decreasing axis might contribute to a better daily living for geriatric patients.• Despite the well-known positive effects on body composition and frailty etc. GH intervention with the intention to treat growth hormone deficiency remain mainly prescribed within younger patients and adults until midlife. Geriatric patients
hormone (GH) secretion and insulin-like growth factor-1 (IGF-1), also known as somatomedin C, which is produced by the liver and other tissues in response to GH. This decline in the secretory activity of the GH–IGF-1 axis has been termed somatopause or hyposomatotropism of aging. Hyposomatotropism of aging is associated with age-related loss of vitality and vigor, muscle mass, and physical function . In addition, frailty, central adiposity, accelerated risks for cardiovascular complications, and deterioration of mental function can occur. [1] The pathophysiology of somatopause is confounded by several variables that can contribute to the decline in GH secretion associated with aging: adiposity, decreased production of sex steroid hormones, decreased physical fitness, fragmented sleep, and malnutrition
hormone (GH) secretion and insulin-like growth factor-1 (IGF-1), also known as somatomedin C, which is produced by the liver and other tissues in response to GH. This decline in the secretory activity of the GH–IGF-1 axis has been termed somatopause or hyposomatotropism of aging. Hyposomatotropism of aging is associated with age-related loss of vitality and vigor, muscle mass, and physical function . In addition, frailty, central adiposity, accelerated risks for cardiovascular complications, and deterioration of mental function can occur. [1] The pathophysiology of somatopause is confounded by several variables that can contribute to the decline in GH secretion associated with aging: adiposity, decreased production of sex steroid hormones, decreased physical fitness, fragmented sleep, and malnutrition
hormone (GH) secretion and insulin-like growth factor-1 (IGF-1), also known as somatomedin C, which is produced by the liver and other tissues in response to GH. This decline in the secretory activity of the GH–IGF-1 axis has been termed somatopause or hyposomatotropism of aging. Hyposomatotropism of aging is associated with age-related loss of vitality and vigor, muscle mass, and physical function . In addition, frailty, central adiposity, accelerated risks for cardiovascular complications, and deterioration of mental function can occur. [1] The pathophysiology of somatopause is confounded by several variables that can contribute to the decline in GH secretion associated with aging: adiposity, decreased production of sex steroid hormones, decreased physical fitness, fragmented sleep, and malnutrition
hormone (GH) secretion and insulin-like growth factor-1 (IGF-1), also known as somatomedin C, which is produced by the liver and other tissues in response to GH. This decline in the secretory activity of the GH–IGF-1 axis has been termed somatopause or hyposomatotropism of aging. Hyposomatotropism of aging is associated with age-related loss of vitality and vigor, muscle mass, and physical function . In addition, frailty, central adiposity, accelerated risks for cardiovascular complications, and deterioration of mental function can occur. [1] The pathophysiology of somatopause is confounded by several variables that can contribute to the decline in GH secretion associated with aging: adiposity, decreased production of sex steroid hormones, decreased physical fitness, fragmented sleep, and malnutrition
The GH/IGF-1 axis in ageing and longevity. Secretion of growth hormone (GH), and consequently that of insulin-like growth factor 1 (IGF-1), declines over time until only low levels can be detected in individuals aged ≥60 years. This phenomenon, which is known as the 'somatopause', has led to recombinant human GH being widely promoted and abused as an antiageing drug, despite lack of evidence
Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy record managers: refer to the Data Element reached the maximum number of saved studies (100).Please remove one or more studies before adding more. Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read